Susan Tebich

Learn More
PURPOSE This trial evaluated the optimum dosing regimen for recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF) to support a dose-intensive chemotherapy regimen given without progenitor cell replacement. PATIENTS AND METHODS Fifty-one patients with refractory malignancy received cyclophosphamide 2,500 mg/m2 on days 1 and 2,(More)
BACKGROUND The Accreditation Council for Graduate Medical Education requires that residents be educated in six general core competencies, but has relied on individual specialties to develop their own definitions, teaching methods and evaluative tools. The Society for Education in Anesthesia took the initiative by organizing a two-day conference to(More)
  • 1